“…IAA-94, indanyloxyacetic acid 94. polyunsaturated fatty acid, arachidonic acid (IC 50 = 8 mM; Kubo and Okada, 1992); oxonol dyes, bis-(1,3dibutylbarbituric acid)pentamethine oxanol (diBA-(5)-C 4 ) (IC 50 = 1.8 mM; Arreola et al, 1995) and WW781 [4-[4-[(1E,3E)-5-(1,3-dibutyl-2,4,6-trioxo-1,3-diazinan-5-ylidene)penta-1,3-dienyl]-3-methyl-5-oxo-4H-pyrazol-1yl]benzenesulfonic acid] (IC 50 = 25 mM; Behe et al, 2017); an antimalaria drug, mefloquine (IC 50 = 1.2 mM; Maertens et al, 2000); a hemichannel blocker, carbenoxolone (CBX) (IC 50 = 15.4 mM; Benfenati et al, 2009); and cell-permeable CFTR inhibitors, GlyH-101 (IC 50 = 5 to 6 mM; Melis et al, 2014) (IC 50 = 9.5 mM; Friard et al, 2017) and 59: 3,4]pyrrolo[1,2-a]quinoxaline-8,10(5H,9)-dione] (IC 50 = 19.6 mM; Friard et al, 2017). Inhibition of VSOR was also reported to be induced by a purinergic P2X receptor blocker, pyridoxalphosphate-6-azophenyl-29,49-disulfonic acid (Galietta et al, 1997;Darby et al, 2003;Poletto Chaves and Varanda, 2008), in a voltage-dependent manner and by unprotonated quinidine in a voltageindependent manner (at pH 9; Voets et al, 1996;Behe et al, 2017). Since the drugs mentioned in this paragraph have no obvious common structural motives, we assume that VSOR channel protein has several pockets (binding sites) of different shapes and electrostatics to accommodate chemical substances of very different structures.…”